Compare Harmony Gold Mining Co. (HMY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs State Street SPDR S&P Biotech ETF — how do they compare? Harmony Gold Mining Co. trades at $15.13 (market cap $9.07B), while State Street SPDR S&P Biotech ETF trades at $153.23. The key difference: Harmony Gold Mining Co. pays a 2.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Harmony Gold Mining Co. nearer its low. Which is the better fit depends on your goals.
| HMY | XBI | |
|---|---|---|
Market Cap | $9.07B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $26.04 | $164.28 |
52-Week Low | $12.61 | $85.16 |
Enterprise Value | $9.41B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $14.37, down 1.91% on the day, amid a bearish technical signal and mixed sentiment. The company shows strong fundamentals with a P/E of 9.37, net income margin of 20.06%, and robust cash flow from operations of $15.65 billion in 2024. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while revenue grew to $61.38 billion in 2024. A dividend of $0.31 is scheduled for payment in May 2026, adding income appeal.
Outlook is cautious due to technical weakness and analyst skepticism (70% hold rating), but valuation metrics and profitability support potential upside if gold prices stabilize. Key risks include Fed rate sensitivity and operational execution amid the transition to a gold-copper hybrid model. The stock presents a value opportunity with manageable debt, though near-term volatility may persist.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
